Direxion Daily S&P Biotech Bear 3X Shares(LABD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$9.11
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LABD

11/20/2026: LABD (1-star) is currently NOT-A-BUY. Pass it for now.

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is a leveraged inverse ETF designed to achieve -3x the daily performance of the S&P Biotechnology Select Industry Index through swap agreements and derivatives. Its primary strength lies in providing high-liquidity, margin-free tactical bearish exposure for active day traders targeting short-term sector downturns. The primary role of the fund is short-term speculation or tactical hedging rather than long-term asset accumulation. Key risks include severe volatility decay, compounding tracking error over extended periods, and extreme vulnerability to sudden bullish sector rallies. It is best suited for experienced, risk-tolerant tactical traders who close positions daily, requiring vigilant monitoring of market momentum and sector catalysts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitGrowth investors seek capital appreciation, which contradicts the short and inverse focus of this fund.
Momentum investorStrong fit while signal remains positiveMomentum traders can utilize LABD to rapidly capitalize on sharp, short-term downward momentum in the biotech sector.
Value investorWeak fitValue investing focuses on fundamentals and long-term holding, whereas LABD is a short-term trading instrument.
Dividend/Income investorWeak fitLABD does not pay meaningful dividends and is built exclusively for capital movement tracking, not income.
Low-risk investorWeak fitThe triple-leveraged inverse structure introduces extreme volatility and risk of rapid capital loss.

Investor Profile

Ideal Investor Profile

Sophisticated day traders and tactical portfolio managers with a high risk tolerance who actively monitor the market and seek short-term bearish exposure to biotech.

Suitability

Strictly suited for active short-term trading and intraday strategies, entirely inappropriate for buy-and-hold or long-term investors.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighThe 3x daily leverage amplifies daily price swings dramatically, exposing capital to severe fluctuations.
Market riskHighAdverse rallies in the biotech sector can instantly and severely erode the value of the fund.
ConcentrationHighThe fund targets a single volatile industry sector (biotechnology), heightening sensitivity to sector-specific shocks.
Tracking/expenseMedium / highCompounding over periods longer than one day can cause returns to diverge significantly from -3x the index return.
LiquidityLowUnderlying market liquidity is strong, though derivative execution costs can impact performance during stressed markets.
Business/sector qualityHighBiotech stocks are heavily influenced by binary events like FDA decisions and clinical readouts, triggering sharp index gaps.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

Extremely high historical volatility resulting from the combined effect of high-beta biotech stocks and 3x daily leverage mechanics.

Market Risk

Vulnerable to sudden upward momentum spikes in the biotech industry, which can result in rapid and substantial losses.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
DerivativesS&P Biotechnology Select Industry Index — seeks -3x daily return100This swap-based structure provides triple inverse daily exposure to the performance of the underlying biotechnology stock index.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type ETF
Historic Profit -46.65%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.